Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was slightly extended in our own case — was refreshing and invigorating, because that oh-so-familiar routine of deadlines, calls, meetings, and the like has, of course, returned. The world, after all, keeps spinning now matter how hard you might push back. So time to fire up the coffee kettle and get cracking. As always, here are some tidbits to get you started. Hope you conquer the world today and please do keep in touch if you hear something juicy or just plain curious. …
Once again, Roche’s (RHHBY) $4.3 billion takeover of Spark Therapeutics (ONCE) has been delayed, possibly beyond the first half of the year, as regulators continue to scrutinize the deal for its effect on competition, Reuters writes. Both companies received a request for more information from the Federal Trade Commission in connection with its review. And the U.K. Competition and Markets Authority has opened an investigation. Roche wants to buy Spark for an experimental gene therapy for hemophilia A and a platform to develop other treatments for genetic diseases.
About the Author Reprints
